Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Monopar Therapeutics has received a consensus recommendation of "Buy" from eight research firms, with an average 1-year price target of $69.57.
• Insider activity shows CEO Chandler Robinson and Director Christopher M. Starr each sold 16,800 shares for a total of $672,000, indicating decreased positions in the company.
• JPMorgan Chase & Co. significantly increased its holdings in Monopar Therapeutics by 1,821%, reflecting strong institutional interest in the stock.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) has received an average recommendation of "Buy" from the nine research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $71.75.

MNPR has been the subject of a number of research analyst reports. Chardan Capital reaffirmed a "buy" rating and set a $60.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, August 13th. Oppenheimer assumed coverage on shares of Monopar Therapeutics in a research note on Wednesday, September 3rd. They set an "outperform" rating and a $77.00 target price for the company. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Raymond James Financial started coverage on Monopar Therapeutics in a report on Tuesday, September 2nd. They issued a "strong-buy" rating and a $80.00 target price on the stock. Finally, BTIG Research started coverage on shares of Monopar Therapeutics in a report on Tuesday. They issued a "buy" rating and a $87.00 target price on the stock.

Insider Buying and Selling

In related news, CEO Chandler Robinson sold 16,800 shares of Monopar Therapeutics stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the transaction, the chief executive officer directly owned 73,472 shares of the company's stock, valued at approximately $2,938,880. The trade was a 18.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher M. Starr sold 16,800 shares of Monopar Therapeutics stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $672,000.00. Following the transaction, the director directly owned 5,173 shares of the company's stock, valued at approximately $206,920. This represents a 76.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,504 shares of company stock valued at $1,700,160. Company insiders own 20.50% of the company's stock.

Hedge Funds Weigh In On Monopar Therapeutics

A number of large investors have recently made changes to their positions in the company. AlphaQuest LLC grew its stake in Monopar Therapeutics by 46.8% in the 2nd quarter. AlphaQuest LLC now owns 1,784 shares of the company's stock worth $64,000 after acquiring an additional 569 shares in the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Monopar Therapeutics in the second quarter valued at approximately $34,000. JPMorgan Chase & Co. grew its stake in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after purchasing an additional 1,821 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Monopar Therapeutics during the 2nd quarter worth $80,000. Finally, New York State Common Retirement Fund bought a new stake in Monopar Therapeutics during the 2nd quarter valued at $104,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR traded down $1.71 during mid-day trading on Friday, hitting $43.23. 5,014 shares of the stock traded hands, compared to its average volume of 39,722. The stock has a fifty day moving average price of $38.67 and a 200-day moving average price of $36.64. The company has a market cap of $266.70 million, a price-to-earnings ratio of -12.98 and a beta of 1.20. Monopar Therapeutics has a 52 week low of $2.40 and a 52 week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.12. As a group, sell-side analysts predict that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.